Call Now

Mouse FABP4 / ALBP / A-FABP Protein (His & MYC Tag)

422/aP2,ALBP/Ap2,Ap2,Lbpl

Catalog Number P50652-M35H
Organism Species Mouse
Host Human Cells
Synonyms 422/aP2,ALBP/Ap2,Ap2,Lbpl
Molecular Weight The recombinant mouse Fabp4 consists of 147 amino acids and predicts a molecular mass of 16.5 kDa.
predicted N His
SDS-PAGE
Purity > 95 % as determined by SDS-PAGE.
Protein Construction A DNA sequence encoding the mouse Fabp4 (NP_077717.1) (Cys2-Ala132) was expressed with a polyhistidine tag at the N-terminus and a myc tag at the C-terminus.
Bio-activity
Research Area Immunology |Signal Transduction |Metabolism |Lipid metabolism
Formulation Lyophilized from sterile 20 mM Tris, 500 mM NaCl, 20 % glycerol, pH 7.4.
1. Normally 5 % - 8 % trehalose and mannitol are added as protectants before lyophilization. Specific concentrations are included in the hardcopy of COA.
Background Mouse fatty acid-binding protein, adipocyte, also known as Adipocyte-type fatty acid-binding protein, Fatty acid-binding protein 4, Adipocyte lipid-binding protein, and FABP4, is a cytoplasm protein which belongs to the calycin superfamily and Fatty-acid binding protein (FABP) family. In familial combined hyperlipidemia (FCHL), FABP4 correlated to body mass index (BMI), waist circumference and homeostasis model assessment (HOMA) index.FABP4 levels were associated with triglyceride-rich lipoproteins. In humans serum FABP4 levels correlate significantly with features of PCOS. It appears to be a determinant of atherogenic dyslipidemia. FABP4 pathway mediates the sebaceous gland hyperplasia in keratinocyte-specific Pten-null mice. FABP4 concentration significantly increased with an increasing of MS features and was strongly correlated with body-mass index, triglycerides, HDL-cholesterol concentrations and blood pressure. Patients in the highest quartile of FABP4 presented a six-fold increased odds ratio for MS and a three-fold increased odds for LD, adjusted by age, sex, body-mass index and the antiretroviral therapy. FABP4 is a strong plasma marker of metabolic disturbances in HIV-infected patients, and therefore, could serve to guide therapeutic intervention in this group of patients.
Reference
  • van Dongen,M.J. et al., 2002, J Am Chem Soc. 124 (40): 11874-80.
  • Coll, B. et al., 2008, Atherosclerosis  199 (1):147-53.
  • Hoashi,S. et al., 2008, BMC Genet. 9 :84.
  • Cai,H. et al., 2010, Bioorg Med Chem Lett  20 (12):3675-9.